Business Wire

Foundation Medicine Expands Immunohistochemistry (IHC) Testing Portfolio to Include MET IHC Testing

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to ...
Cure Today

IHC Testing Aims to Expand Personalized Treatment in Lung Cancer

Caris Life Sciences aims to standardize MET immunohistochemistry testing for non-squamous non-small cell lung cancer to enhance molecular insights and treatment personalization. MET protein expression ...
Insider Monkey

Guardant Health (GH) introduces IHC Solid Tumor Testing to its Portfolio

On May 21, Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular profiling tests. This addition will help oncologists identify the ...
Seeking Alpha

Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors

Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test PALO ALTO, Calif.--(BUSINESS WIRE)-- ...
FierceBiotech

Ventana launches first fully automated IHC test to detect BRAF V600E mutation in a variety of cancers

"As a leader in cancer diagnostics, Ventana is committed to providing unique immunohistochemistry assays for aiding in the diagnosis and management of a variety of cancers," says Ventana President ...
ascopubs.org

Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies

Pediatric Precision Medicine at the National Cancer Center Japan: Prospective Genomic Study of Pediatric Patients with Cancer as Part of the TOP-GEAR Project HER2 status was evaluated using ...
Business Wire

Publication Describes New International Consortium Standardizing Immunohistochemistry

BOSTON--(BUSINESS WIRE)--Boston Cell Standards, a company standardizing tumor tissue testing with the first immunohistochemistry laboratory reference standards, announced the publication of a journal ...

Boston Cell Standards Enters Final Phase of FDA MDDT Program to Qualify First-in-Industry Platform to Standardize Cancer Diagnostic Assays

Boston Cell Standards, Inc. (BCS), a private company bringing modern Quality tools and practices to Clinical ...
The American Journal of Managed Care

Real-World Insights on Biomarker Testing Patterns and Implications for mNSCLC Therapy Selection

Background: Biomarker testing is essential for guiding first-line treatment decisions in metastatic non–small cell lung cancer (mNSCLC). Despite guideline recommendations, real-world testing patterns ...
EurekAlert!

European multicenter harmonization study shows anaplastic lymphoma kinase immunohistochemistry testing comparable to, if not better than, fluorescence in situ hybridization testing

DENVER – Sixteen institutions across Europe collaborated together to show for the first time that a semi-quantitative anaplastic lymphoma kinase (ALK) protein expression test, immunohistochemistry ...
ascopubs.org

HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary

Clinical questions 3, 4, and 5 address less common result groups observed when performing dual-probe ISH testing as described below. 9,10 Since 2013, several laboratory and clinical investigators ...